A Agilent Technologies Inc.

Agilent Brings Greater Clarity and Speed to Chemical Imaging

(NYSE: A) today introduced a new approach to chemical imaging that will bring greater clarity and unprecedented speed to pharmaceutical, biomedical, food, and materials science.

The chemical imaging system represents a breakthrough in both chemical imaging and spectral analysis.

“This ‘walk-up’ solution provides high-definition chemical imaging more rapidly and accurately than ever, to aid in analyzing the composition of tablets, laminates, tissues, polymers, and fibers,” said Phil Binns, vice president and general manager of Agilent’s Spectroscopy division. “With this information, scientists can analyze more samples and in greater detail in minutes instead of hours.”

Binns noted that the new system would have a significant impact on pharmaceutical laboratories in particular “scientists will be able to make more informed decisions—in less time—in product formulation development and trouble-shooting.”

Using the 8700 LDIR, scientists can obtain actionable information about active pharmaceutical ingredients, excipients, polymorphs, salts, and defects to enable users to quickly identify and resolve issues experienced during drug development. Simply put, the 8700 has the potential to enable labs to bring pharmaceutical products to market faster and with greater confidence in their formulations.

The 8700 LDIR combines unique Quantum Cascade Laser (QCL) technology with rapid scanning optics and intuitive Agilent Clarity software. Importantly, the system produces images free from laser coherence artifacts to provide high definition images of large areas.

The 8700 LDIR system’s compact size, lack of liquid nitrogen, and automated operation make high-definition chemical imaging accessible to operators of all levels. Now users can minimize time spent on sample analysis and data review, which leads to increased productivity. Simple load-and-go methods also save time and make it ideal for walk-up use in both commercial and academic settings.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,200 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to our . Follow on , , and .

EN
01/10/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Key facts and statistics - fiscal 2025

A summary company profile, detailing Agilent Technologies, Inc.’s business operations and financial highlights.

Agilent Technologies, Inc. - October 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch